SARS-CoV-2-IN-14 |
| Catalog No.GC69860 |
SARS-CoV-2-IN-14 (compound 6) is an effective inhibitor of SARS-CoV-2 with an IC50 of 0.39 μM. It is a chloronitroaniline analog. SARS-CoV-2-IN-14 has higher stability in human plasma and liver S9 enzyme assays compared to chloronitroaniline, and oral administration can improve its bioavailability and half-life.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 22203-98-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Review for SARS-CoV-2-IN-14
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for SARS-CoV-2-IN-14
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *